11.15.22 -- Five Questions That Determine The Success Of Your PROTAC Programs

Proteolysis-targeting chimeras (PROTACs) and other protein degradation strategies offer benefits in drug discovery for challenging targets. Discover considerations when launching a PROTAC development program.

Size exclusion chromatography is the go-to analytical method for therapeutic protein drugs. This article describes the factors affecting the reproducibility of columns and how you can minimize column variation.

Learn more about developed and qualified SPR assays to characterize the binding and affinity of biosimilar and innovator nivolumab for all seven Fc gamma receptors, FcRn, and PD-1.

Since physical structure and biological activity are directly linked, controlling the physical form of a compound is paramount to a final drug product’s quality and effectiveness.

This application note demonstrates systems that have proven quite useful for clarification of mammalian cell cultures such as CHO-cells by combining the cell clearance and sterile filtration functionality in a single device.

A pharmaceutical company sought a development and manufacturing partner to assist with an in-licensed product originating from an emerging pharma company, a molecule in clinical Phase 2/3 trials.

Lonza Pharma & Biotech’s Jonas Mueller and Nikolay Krumov answer attendee questions from a recent webinar about the pros and cons of soluble and insoluble processes as well as other related topics.

See how experience, targeted testing, and basic scientific principles can quickly lead to the selection of effective and commercially viable formulations at an early stage of the development cycle.